Sydney, Australia, May 2019
AMSL Diabetes are excited to announce that they have signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) to introduce their patient-focused therapies to the Australian market.
The exclusive partnership is set to benefit Australian diabetes patients by offering a new innovative technology solution for their diabetes management.
“We are excited to partner with AMSL Diabetes to bring our products to Australia” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “Our founder, Alfred Mann, had a vision to bring our product to a worldwide market and with AMSL’s presence and knowledge of the diabetes market in Australia, we believe we will reach healthcare providers and patients with the message that our product is an incredible option in the fight against diabetes.”
MannKind Corporation will retain responsibility for product development, quality management and manufacturing while AMSL Diabetes will be responsible for regulatory and reimbursement approval, sales, marketing, customer support and distribution activities within Australia.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialisation of inhaled therapeutic products with medical conditions such as diabetes and pulmonary arterial hypertension. MannKind is headquartered in Westlake Village, California and has a state-of-the-art manufacturing and research facility in Danbury, Connecticut.
Now you can get all the latest news and updates of our products, events and resources right into your inbox.
We are always happy to help, send us a message or enquiry